Johnson & Johnson May Be Forced To License Stents Patents To Complete Major Acquisition

Law360, New York (August 29, 2005, 12:00 AM EDT) -- The European Commission ruled this week Johnson & Johnson may need to license Guidant Corp.’s patents, which are held up in litigation, before acquisition of Guidant will be granted final approval.

The $25 billion dollar cash and stock deal would be the largest ever in the medical device industry and biggest in the 118-year history of Johnson & Johnson, maker of drugs, baby products, orthopedic and other health products.

Johnson & Johnson and Guidant are active worldwide in vascular medical devices, with their products used to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.